International Psoriasis Council

Advancing Knowledge. Improving Care.

Huidi

Shucheng

,

MD, PhD, MPH

Dermatologist/Research Scientist
West China Hospital, Sichuan University
Chengdu
,
China
2024 Fellow
Dr. Huidi Shucheng is an attending dermatologist in the Department of Dermatology and Venereology at West China Hospital, Sichuan University. In this role, he co-leads the psoriasis comorbidity multidisciplinary team, oversees the psoriasis long-term management clinic, and manages the dermatology–rheumatology clinic. Additionally, he conducts research in the Laboratory of Dermatology at the Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease Related Molecular Network, West China Hospital, Sichuan University. He is a lecturer at West China School of Medicine, Sichuan University, focusing on clinical and laboratory research and education in psoriasis. Currently, he is a postdoctoral scientist at Cedars Sinai Medical Center in Los Angeles, California, where he further explores basic and translational research in psoriasis, including novel pathway discovery and biomarker validation. Dr. Shucheng’s clinical and research interests include immune-mediated and inflammatory skin diseases, particularly psoriasis, novel therapeutics and biosimilars, difficult-to-treat areas such as nail psoriasis, patient education and advocacy, and translational dermatology and immunology. He has presented at national and international congresses and published in leading peer-reviewed journals. His honors include the World Congress of Dermatology (WCD) Rising Star Scholarship, the International Societies for Investigative Dermatology (ISID) Asia/Oceania Travel Grant, the European Academy of Dermatology and Venereology Health Care Professionals (EADV HCP) Scholarship, and the Society for Investigative Dermatology (SID) Future Leader Award. Dr. Shucheng studied with IPC Board Member Joel Gelfand at the University of Pennsylvania in Philadelphia, Pennsylvania, United States.
Last Updated:
07/03/2025

Areas of Interest

Novel therapeutics and biosimilars; Clinical and translational research; Psoriasis comorbidities; Patient education and advocacy

Languages Spoken

Chinese, English, Japanese

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026